¹⁷⁷Lu-PSMA-617

Quick Answer

¹⁷⁷Lu-PSMA-617 is a small-molecule radioligand that binds prostate-specific membrane antigen (PSMA) on prostate cancer cells and delivers targeted beta radiation. It is given as 7.4 GBq (200 mCi) IV every 6 weeks for up to 6 cycles to patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). Patients are selected by PSMA-PET (± FDG-PET). Lu-177's imageable gamma emissions allow post-therapy SPECT/CT to confirm delivery and support dosimetry.

Clinical Importance

This was the first PSMA-targeted radioligand therapy to show an overall-survival benefit in a randomized trial (VISION), establishing radioligand therapy as a standard option in advanced prostate cancer. Its label has since expanded to earlier use, making it relevant to a large and growing patient population and a central workload in most theranostics programs.

Evidence & Indication

• VISION (2021): in PSMA-positive mCRPC previously treated with an androgen-receptor pathway inhibitor (ARPI) and taxane chemotherapy, ¹⁷⁷Lu-PSMA-617 plus standard care improved overall survival and radiographic progression-free survival versus standard care alone. This supported the initial FDA approval (2022).
• PSMAfore: extended benefit to patients who had progressed on an ARPI but had not yet received taxane chemotherapy. On this basis the FDA expanded the label in 2025 to earlier (pre-chemotherapy) use in PSMA-positive mCRPC after ARPI, for patients who are candidates to delay taxane chemotherapy.

Confirm the current approved indication and local funding at time of use, as this label has moved.

Patient Selection

• Histologically confirmed mCRPC with prior ARPI therapy (± taxane depending on line of therapy).
• PSMA-avid disease on PSMA-PET meeting eligibility criteria (adequate uptake in target lesions).
• Adequate marrow, renal, and hepatic function.
• Discordance matters: FDG-positive but PSMA-negative lesions predict poorer benefit; dual FDG/PSMA imaging is used in many centers to exclude significant PSMA-negative disease.

Preparation

Baseline labs (CBC, renal and hepatic function, PSA), review of PSMA-PET eligibility, hydration, and patient counseling on radiation-safety precautions. Antiemetic prophylaxis as needed.

Workflow

Confirm PSMA positivity → baseline labs and dosimetry considerations → outpatient IV administration with hydration → post-therapy SPECT/CT (optional, to confirm biodistribution) → interval labs and PSA → reassess before each subsequent cycle.

Dose

7.4 GBq (200 mCi) per cycle, every 6 weeks, up to 6 cycles, in PSMA-positive mCRPC after ARPI (± taxane). Cycles may be held or dose-reduced for toxicity per protocol.

Monitoring

CBC (myelosuppression), renal function, hepatic function, and PSA between cycles. Watch for cumulative marrow and renal effects across cycles.

Radiation Safety

Lu-177 is typically administered on an outpatient basis. Patients receive instructions on distancing from others (especially children and pregnant persons), hygiene, and handling of body fluids for a defined period. Follow institutional and regulatory release criteria.

Expected Outcomes

Improved overall and radiographic progression-free survival and PSA responses in appropriately selected patients; a meaningful proportion achieve significant PSA decline. Benefit correlates with the degree and extent of PSMA expression.

Complications & Toxicities

• Xerostomia (dry mouth) and dry eyes from salivary/lacrimal PSMA expression — the most characteristic toxicity, though generally milder than with alpha-labeled PSMA agents.
• Myelosuppression (anemia, thrombocytopenia, neutropenia).
• Fatigue, nausea.
• Renal effects — kidneys are a dose-limiting organ; monitor function.

Dose Modification & Holding Rules

Cycles are individualized to tolerance rather than given rigidly. Common protocol levers: hold or delay a cycle for grade ≥3 hematologic toxicity, significant renal decline, or unresolved xerostomia/other toxicity, resuming when recovered; dose-reduce (e.g. to ~6.0 GBq) for persistent grade 2–3 marrow toxicity; and discontinue for progression, unacceptable toxicity, or completion of the planned six cycles. Recovery of counts and renal function is confirmed before each administration, and dosimetry-guided approaches may extend or personalize the schedule in selected programs.

Managing the Characteristic Toxicities

• Xerostomia / dry eyes: salivary and lacrimal PSMA expression drives this; supportive care (hydration, saliva substitutes, sugar-free stimulants) is mainstay. Salivary-gland protection strategies (cooling, sialagogues) have been studied with mixed results; xerostomia is generally milder than with alpha-labeled PSMA agents.
• Myelosuppression: monitor CBC each cycle; cumulative marrow dose matters — prior chemotherapy, marrow disease, and extensive skeletal tumor burden raise risk.
• Renal protection: kidneys are a dose-limiting organ; ensure hydration and track function across cycles, as renal dose is cumulative.
• Fatigue and nausea: usually manageable with standard supportive measures and antiemetics.

Sequencing & Retreatment

Optimal positioning relative to taxane chemotherapy, ARPI switch, and Ra-223 is evolving. TheraP established activity versus cabazitaxel, and PSMAfore/ENZA-p extended benefit earlier and in combination — but sequencing is individualized to prior therapies, disease burden, and patient preference. Retreatment ("re-challenge") with additional cycles after an initial response and later progression is used in some centers with reported benefit, though it remains a pragmatic, not firmly protocolized, strategy; confirm persistent PSMA avidity before re-treating.

Response Assessment

PSA trend, conventional imaging, and PSMA-PET using RECIP 1.0. Post-therapy SPECT/CT can confirm tumor targeting and enables dosimetry. Discordant responses (PSA vs imaging) occur — interpret together, and remember an early PSA rise can reflect flare rather than progression. See the theranostics response-criteria page.

Self-Check

Key References

• Sartor O, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer (VISION). N Engl J Med. 2021;385:1091–1103.
• Morris MJ, et al. PSMAfore: ¹⁷⁷Lu-PSMA-617 versus ARPI change in taxane-naïve mCRPC.
• SNMMI/EANM procedure guideline for ¹⁷⁷Lu-PSMA radioligand therapy.